AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

U.S. infectious disease expert Anthony Fauci said on Wednesday that AstraZeneca's decision to pause global trials of its ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Thursday reported third-quarter net income of $2.53 billion. On a per-share basis, the Cambridge, Britain-based company ...

The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry ...